The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses (reply)

Haematologica

Volumn 96, Issue 4, 2011, Pages

  Visani, Giuseppe ^a   Breccia, Massimo ^b   Montefusco, Enrico ^b   Morra, Enrica ^c   Santini, Valeria ^d   Isidori, Alessandro ^c  

^a SAN SALVATORE HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; CANCER RESISTANCE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MEGADOSE; DRUG WITHDRAWAL; HEART DISEASE; HUMAN; HYPERTENSION; LETTER; LOW DRUG DOSE; LUNG DISEASE; PERICARDIAL EFFUSION; PLEURA EFFUSION; SKIN DISEASE; TREATMENT DURATION;

HUMANS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PERICARDIAL EFFUSION; PLEURAL EFFUSION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 79953841868     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.041319     Document Type: Letter

References (6)

1. Krauth M-T, Herndlhofer S, Schmook M-T, Mitterbauer-Hohendanner G, Schlögl E, and Valent P. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica. 2011;96 (01):163-6.
2. Quintás-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R, Cortes J. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908-14.
3. de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141(5):745-7.
4. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116(2):377-86.
5. Visani G, Breccia M, Gozzini A, Specchia G, Montefusco E, Morra E, et al. Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients. Am J Hematol. 2010; 85(12):960-3.
6. Breccia M, Alimena G. Pleural/pericardic effusions during dasa-tinib treatment: incidence, management and risk factors associated to their development. Expert Opin Drug Saf. 2010;9(5):713-21.